Literature DB >> 23255912

Molecular characterisation of gastrointestinal stromal tumours in a South African population.

Gillian Baker1, Chantal Babb, Desmond Schnugh, Simon Nayler, Melanie Louw, Jacqueline Goedhals, Pierre-Paul Bringuier, Jean-Yves Blay, Pascale Willem.   

Abstract

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the digestive tract. Pathogenesis is linked to activating mutations identified in two proto-oncogenes, v-kit Hardy/Zuckerman 4 feline sarcoma viral oncogene homologue KIT (KIT) and the platelet-derived growth factor α (PDGFRα). In addition, these mutations affect response to treatment with tyrosine kinase inhibitors. In the present study, we report on the molecular characterisation of GISTs in the South African population. Tumour DNA was extracted from 46 GIST samples, followed by cycle sequencing of KIT exons 11, 13 and 17 and PDGFRα exons 12, 14 and 18. Fragment length analysis was used to detect a 6-bp duplication in KIT exon 9. Wild-type duplications were analysed further by PCR and sequencing of additional KIT and PDGFRα exons was performed. Overall, 78.3% of the samples had a mutation in KIT or PDGFRα. Of these, mutations were detected in KIT exon 11 (88.9%), PDGFRα exon 18 (8.3%) and KIT exon 9 (2.8%). Mutations varied from simple substitutions and duplications to large deletions (some with nucleotide insertions) resulting in missense mutations. In addition, seven single nucleotide polymorphisms were detected in 17 patients, one of which appears novel. The incidence of mutations in KIT exon 11 and PDGFRα exon 18 is consistent with the literature, however, the low incidence of KIT exon 9 mutations detected was unexpected. In contrast to previous western and Asian studies, this mutation appears to be rare in the South African population. The present study contributes to the molecular understanding of GISTs in the South African population.

Entities:  

Year:  2012        PMID: 23255912      PMCID: PMC3525459          DOI: 10.3892/ol.2012.1013

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

Review 1.  Gastro-intestinal stromal tumours (GISTs) - the Pretoria experience and a literature review.

Authors:  R J Hartley; J H R Becker; H Van der Walt; T Luvhengo
Journal:  S Afr J Surg       Date:  2011-08-31       Impact factor: 0.375

2.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

3.  Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

Authors:  Markku Miettinen; Hala Makhlouf; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

4.  Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene.

Authors:  G Stenman; A Eriksson; L Claesson-Welsh
Journal:  Genes Chromosomes Cancer       Date:  1989-11       Impact factor: 5.006

5.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Authors:  Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

6.  Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.

Authors:  Satoru Yuzawa; Yarden Opatowsky; Zhongtao Zhang; Valsan Mandiyan; Irit Lax; Joseph Schlessinger
Journal:  Cell       Date:  2007-07-27       Impact factor: 41.582

Review 7.  Biology of gastrointestinal stromal tumors.

Authors:  Christopher L Corless; Jonathan A Fletcher; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

Review 8.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Authors:  J Lasota; M Miettinen
Journal:  Histopathology       Date:  2008-02-28       Impact factor: 5.087

9.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

10.  C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal.

Authors:  S Sakurai; T Fukasawa; J M Chong; A Tanaka; M Fukayama
Journal:  Jpn J Cancer Res       Date:  1999-12
View more
  3 in total

1.  Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases.

Authors:  Ming Wang; Jia Xu; Wenyi Zhao; Lin Tu; Weiqing Qiu; Chaojie Wang; Yangyin Shen; Qiang Liu; Hui Cao
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

2.  Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor: determination of frequency, distribution pattern and identification of novel mutations in Indian patients.

Authors:  Firoz Ahmad; Purnima Lad; Simi Bhatia; Bibhu Ranjan Das
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

3.  Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience.

Authors:  Trupti Pai; Munita Bal; Omshree Shetty; Mamta Gurav; Vikas Ostwal; Anant Ramaswamy; Mukta Ramadwar; Sangeeta Desai
Journal:  South Asian J Cancer       Date:  2017 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.